Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOramed Pharmaceuticals Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q2 2025 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q3 2025 | 1 | -$0.07 | -$0.07 | -$0.07 |
| Q4 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
Oramed Pharmaceuticals Inc. Earnings Date And Information
Oramed Pharmaceuticals Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.00846 by $0.21154. The company had revenue of 0 for the quarter and had revenue of 1.34 M for the year. Oramed Pharmaceuticals Inc. has generated $0 earnings per share over the last year ($0.14 diluted earnings per share) and currently has a price-to-earnings ratio of 22.35. Oramed Pharmaceuticals Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based on prior year's report dates.
Oramed Pharmaceuticals Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.48 | $250,000 | $0 | ||
| 08/14/2024 | Q2 2024 | $0.01 | $0.22 | 0.21 | $250,000 | $0 |
| 05/09/2024 | Q1 2024 | $0.02 | $0.04 | 0.02 | $0 | |
| 03/06/2024 | Q4 2023 | -$0.12 | $0.00 | $0 | ||
| 11/09/2023 | Q3 2023 | -$0.09 | -$0.08 | 0.01 | $700,000 | $0 |
| 08/10/2023 | Q2 2023 | -$0.11 | -$0.03 | 0.08 | $700,000 | $674,000 |
| 05/11/2023 | Q1 2023 | -$0.23 | -$0.04 | 0.19 | $666,000 | |
| 03/06/2023 | Q4 2022 | -$0.22 | -$0.22 | 0 | $681,000 | |
| 11/10/2022 | Q3 2022 | -$0.26 | -$0.19 | 0.07 | $696,833 | $682,000 |
| 08/10/2022 | Q2 2022 | -$0.22 | -$0.27 | -0.05 | $700,000 | $674,000 |
| 05/12/2022 | Q1 2022 | -$0.23 | -$0.27 | -0.04 | $666,000 | |
| 01/11/2022 | Q4 2021 | -$0.20 | -$0.22 | -0.02 | $674,000 | |
| 11/24/2021 | Q3 2021 | -$0.10 | -$0.23 | -0.13 | $683,000 | |
| 07/14/2021 | Q2 2021 | -$0.12 | -$0.17 | -0.05 | $681,000 | |
| 04/13/2021 | Q1 2021 | -$0.19 | -$0.17 | 0.02 | $665,000 | |
| 01/14/2021 | Q4 2020 | -$0.16 | -$0.23 | -0.07 | $674,000 | |
| 11/24/2020 | Q3 2020 | -$0.15 | -$0.13 | 0.02 | $681,000 | |
| 07/07/2020 | Q2 2020 | -$0.15 | -$0.10 | 0.05 | $681,000 | |
| 04/06/2020 | Q1 2020 | -$0.25 | -$0.21 | 0.04 | $674,000 | |
| 01/09/2020 | Q4 2019 | -$0.26 | -$0.15 | 0.11 | $674,000 |
Oramed Pharmaceuticals Inc. Earnings: FAQ's
When is Oramed Pharmaceuticals Inc.'s earnings date?
Oramed Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based off last year's report dates.
Did Oramed Pharmaceuticals Inc. beat their earnings estimates last
quarter?
In the previous quarter, Oramed Pharmaceuticals Inc. (:ORMP) reported $0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $0.00846 by $0.21154.
How can I listen to Oramed Pharmaceuticals Inc.'s earnings conference
call?
The conference call for Oramed Pharmaceuticals Inc.'s latest earnings report can be listened to online.
How can I read Oramed Pharmaceuticals Inc.'s conference call transcript?
The conference call transcript for Oramed Pharmaceuticals Inc.'s latest earnings report can be read online.
How much revenue does Oramed Pharmaceuticals Inc. generate each year?
Oramed Pharmaceuticals Inc. (:ORMP) has a recorded annual revenue of $1.34 M.
How much profit does Oramed Pharmaceuticals Inc. generate each year?
Oramed Pharmaceuticals Inc. (:ORMP) has a recorded net income of $1.34 M. Oramed Pharmaceuticals Inc. has generated $0.14 earnings per share over the last four quarters.
What is Oramed Pharmaceuticals Inc.'s price-to-earnings ratio?
Oramed Pharmaceuticals Inc. (:ORMP) has a price-to-earnings ratio of 22.35 and price/earnings-to-growth ratio is -0.1.